Antipsychotics inhibit glucose transport: Determination of olanzapine binding site inStaphylococcus epidermidis glucose/H+ symporter
Open Access
- 1 January 2015
- journal article
- Published by Wiley in FEBS Open Bio
- Vol. 5 (1) , 335-340
Abstract
The antipsychotic drug olanzapine is widely prescribed to treat schizophrenia and other psychotic disorders. However, it often causes unwanted side effects, including diabetes, due to disruption of insulin‐dependant glucose metabolism through a mechanism yet to be elucidated. To determine if olanzapine can affect the first step in glucose metabolism – glucose transport inside cells – we investigated the effect of this drug on the transport activity of a model glucose transporter. The glucose transporter fromStaphylococcus epidermidis (GlcPSe) is specific for glucose, inhibited by various human glucose transporter (GLUT) inhibitors, has high sequence and structure homology to GLUTs, and is readily amenable to transport assay, mutagenesis, and computational modeling. We found that olanzapine inhibits glucose transport of GlcPSe with an IC50 0.9 ± 0.1 mM. Computational docking of olanzapine to the GlcPSe structure revealed potential binding sites that were further examined through mutagenesis and transport assay to identify residues important for olanzapine inhibition. These investigations suggest that olanzapine binds in a polar region of the cytosolic part of the transporter, and interacts with residues R129, strictly conserved in all GLUTs, and N136, conserved in only a few GLUTs, including the insulin‐responsive GLUT4. We propose that olanzapine inhibits GlcPSe by impeding the alternating opening and closing of the substrate cavity necessary for glucose transport. It accomplishes this by disrupting a key salt bridge formed by conserved residues R129 and E362, that stabilizes the outward‐facing conformation of the transporter.Keywords
Funding Information
- NIH (R01-DK091754)
This publication has 35 references indexed in Scilit:
- Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesBMJ, 2011
- Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism DysregulationCNS Drugs, 2010
- Glucose transporters in the 21st CenturyAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- GLUT4 Overexpression or Deficiency in Adipocytes of Transgenic Mice Alters the Composition of GLUT4 Vesicles and the Subcellular Localization of GLUT4 and Insulin-responsive AminopeptidaseJournal of Biological Chemistry, 2004
- OlanzapineDrugs, 2001
- Anxious?depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?Schizophrenia Research, 1999
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance.Journal of Clinical Investigation, 1998
- Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects.Journal of Clinical Investigation, 1995